CTI Invest has more than 80 members
25.05.2012
Three biotech start-ups presented at CTI Invests 37th Swiss Venture Day and these top players in the field of life sciences met with great interest among investors. At the previous AGM of the association, Philip Bodmer of Startangels and Christian Nagel of Earlybird were elected to the board.
“For the first time, we have more than 80 institutional and private investors as members,” announced Jean-Pierre Vuilleumier, managing director of the investor association CTI Invest, at Thursday’s meeting. Newly elected to the board were Philip Bodmer from the business angel club Startangels and Christian Nagel, founder and partner of German equity firm Earlybird.
Yesterday’s meeting of the members of CTI Invest at ETH Zurich also included the conclusion of the business plan competition >>venture 2012>> with the presentations of the best 17 projects. However, it was the founding teams of the three biotech companies who convinced everyone. “These are three top companies,” commented managing director Vuilleumier. And these are the top three companies:
BioVersys
Antibiotic resistance is a significant and increasing problem for hospital-acquired bacterial infections. BioVersys develops compounds that block antibiotic resistance and thus restore the efficacy of approved antibiotics. The resulting fixed combination drugs enter a market of high unmet medical need.
Antibiotic resistance is a significant and increasing problem for hospital-acquired bacterial infections. BioVersys develops compounds that block antibiotic resistance and thus restore the efficacy of approved antibiotics. The resulting fixed combination drugs enter a market of high unmet medical need.
Biognosys
Biognosys has developed a solution to quantify proteins from a drop of blood. With a novel mass spectrometric technology, it can record protein signals from 1000s of proteins in a single instrument run. This enables individual protein levels to be monitored for the early detection of diseases and thus represents the key to personalised medicine.
Biognosys has developed a solution to quantify proteins from a drop of blood. With a novel mass spectrometric technology, it can record protein signals from 1000s of proteins in a single instrument run. This enables individual protein levels to be monitored for the early detection of diseases and thus represents the key to personalised medicine.
Virometix
A vaccine is a non-hazardous version of a pathogen produced either in a nutrient solution or by genetically altered bacteria – until now, that is, because Virometix has created a broadly applicable technology platform for the chemical manufacture of vaccines. Such a manufacturing process is not only simpler and more cost-efficient, but also safer.
A vaccine is a non-hazardous version of a pathogen produced either in a nutrient solution or by genetically altered bacteria – until now, that is, because Virometix has created a broadly applicable technology platform for the chemical manufacture of vaccines. Such a manufacturing process is not only simpler and more cost-efficient, but also safer.
0Comments
Please login or sign up to comment.
Commenting guidelines